Page 611«..1020..610611612613

Dendreon leads drug stocks higher – MarketWatch

By Dr. Matthew Watson


Artuji
Dendreon leads drug stocks higher
MarketWatch
The NYSE Arca Pharmaceutical Index (INDEX:DRG) edged up 0.4% at 299.09 and the NYSE Arca Biotechnology Index (INDEX:BTK) rose 0.7% to 1227.88.
Dendreon's Clean Bill Of HealthForbes
Major turnaround for Dendreon as US FDA approves Provenge for advanced ...The Pharma Letter
Dendreon Shares Pop On Provenge ApprovalDaily Markets
Orange County Business Journal -Puget Sound Business Journal -Comtex Smartrend
all 976 news articles »

To Read More: Dendreon leads drug stocks higher – MarketWatch
categoriaUncategorized commentoComments Off on Dendreon leads drug stocks higher – MarketWatch | dataMay 2nd, 2010
Read All

More about presentations at AACR10

By Dr. Matthew Watson

Five presentations at the 101th annual meeting of the American Association of Cancer Research were highlighted a news release from Geron Corporation (dated March 3, 2010). One presentation that had an explicit focus on CSC was this poster:

Imetelstat, a telomerase inhibitor in phase I trials in solid tumor and hematological malignancies, has broad activity against multiple types of cancer stem cells [Presentation Abstract].

Also mentioned in the news release was an oral presentation by Jerry W Shay, given as part of the Major Symposium entitled: Role of Telomeres and Telomerase in Chromosomal Stability and Disease [Session Detail]. The presentation was:

Role of telomerase in normal and neoplastic stem cells [Presentation Abstract].

Another poster about the telomerase inhibitor imetelstat (GRN163L) was:

Sensitivity and resistance of non-small cell lung cancer to the telomerase inhibitor imetelstat [Presentation Abstract].

Comments: A search of the ClinicalTrials.gov database for GRN163L revealed 6 trials. Four were ongoing, but not recruiting participants. Two were still recruiting: 1) Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies; 2) A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer.

An analogous search for imetelstat yielded the same 6 trials. All 6 trials have been sponsored by Geron Corporation.

To Read More: More about presentations at AACR10
categoriaStem Cell Therapy commentoComments Off on More about presentations at AACR10 | dataMay 2nd, 2010
Read All

Dendreon’s Clean Bill Of Health – Forbes

By Dr. Matthew Watson


Santa Barbara Independent
Dendreon's Clean Bill Of Health
Forbes
One of the most controversial biotechnology companies of the past decade is poised to become one of the most successful. The Food and Drug Administration ...
FDA approves country's first cancer treatment vaccineSeattle Times
FDA Approves Drug for Company with Seal Beach PlantOrange County Business Journal
Business Journal Live on the Eastside with Dendreon Chief Dr. Mitchell GoldPuget Sound Business Journal
Comtex Smartrend -Reuters -Santa Barbara Independent
all 695 news articles »

To Read More: Dendreon’s Clean Bill Of Health – Forbes
categoriaUncategorized commentoComments Off on Dendreon’s Clean Bill Of Health – Forbes | dataApril 30th, 2010
Read All

Latest Cell Therapy Approval by FDA. Dendreon’s Provenge.

By Dr. Matthew Watson

It has been a long-time coming. It has been hyped and scoffed, bet against and hoped for, but now none of that matters. It's here. Dendreon has brought Provenge to market. Here, in the word's of the FDA...

FDA NEWS RELEASE

For Immediate Release: April 29, 2010

FDA Approves a Cellular Immunotherapy for Men with Advanced Prostate Cancer

The U.S. Food and Drug Administration today approved Provenge (sipuleucel-T), a new therapy for certain men with advanced prostate cancer that uses their own immune system to fight the disease.

Provenge is indicated for the treatment of asymptomatic or minimally symptomatic prostate cancer that has spread to other parts of the body and is resistant to standard hormone treatment.

Prostate cancer is the second most common type of cancer among men in the United States, behind skin cancer, and usually occurs in older men. In 2009, an estimated 192,000 new cases of prostate cancer were diagnosed and about 27,000 men died from the disease, according to the National Cancer Institute.

“The availability of Provenge provides a new treatment option for men with advanced prostate cancer, who currently have limited effective therapies available,” said Karen Midthun, M.D., acting director of the FDA’s Center for Biologics Evaluation and Research.

Provenge is an autologous cellular immunotherapy, designed to stimulate a patient’s own immune system to respond against the cancer. Each dose of Provenge is manufactured by obtaining a patient’s immune cells from the blood, using a machine in a process known as leukapheresis. To enhance their response against the cancer, the immune cells are then exposed to a protein that is found in most prostate cancers, linked to an immune stimulating substance. After this process, the patient’s own cells are returned to the patient to treat the prostate cancer. Provenge is administered intravenously in a three-dose schedule given at about two-week intervals.

The effectiveness of Provenge was studied in 512 patients with metastatic hormone treatment refractory prostate cancer in a randomized, double-blind, placebo-controlled, multicenter trial, which showed an increase in overall survival of 4.1 months. The median survival for patients receiving Provenge treatments was 25.8 months, as compared to 21.7 months for those who did not receive the treatment.

Almost all of the patients who received Provenge had some type of adverse reaction. Common adverse reactions reported included chills, fatigue, fever, back pain, nausea, joint ache and headache. The majority of adverse reactions were mild or moderate in severity. Serious adverse reactions, reported in approximately one quarter of the patients receiving Provenge, included some acute infusion reactions and stroke. Cerebrovascular events, including hemorrhagic and ischemic strokes, were observed in 3.5 percent of patients in the Provenge group compared with 2.6 percent of patients in the control group.

Provenge is manufactured by Seattle-based Dendreon Corp.

To Read More: Latest Cell Therapy Approval by FDA. Dendreon’s Provenge.
categoriaRegenerative Medicine commentoComments Off on Latest Cell Therapy Approval by FDA. Dendreon’s Provenge. | dataApril 30th, 2010
Read All

Malaysia To Showcase Bio-Xcell, Biotech Advantages At BIO Chicago – Bernama

By Dr. Matthew Watson


Earthtimes (press release)
Malaysia To Showcase Bio-Xcell, Biotech Advantages At BIO Chicago
Bernama
The 70-member delegation, with extensive biotechnology background, will "rub shoulders" with Who's Who in the biotechnology industry to convince them on the ...
Tennessee Biotechnology Association Announces Speaker Lineup for BIO ...Earthtimes (press release)
Baxter Welcomes BIO 2010 International Convention to ChicagoMarketWatch (press release)
2010 BIO International Convention Exhibitor ProfilesBusiness Wire (press release)
PR Newswire (press release) -Bradenton Herald
all 132 news articles »

To Read More: Malaysia To Showcase Bio-Xcell, Biotech Advantages At BIO Chicago – Bernama
categoriaUncategorized commentoComments Off on Malaysia To Showcase Bio-Xcell, Biotech Advantages At BIO Chicago – Bernama | dataApril 30th, 2010
Read All

BioCryst rallies on gout study; indices diverge – MarketWatch

By Dr. Matthew Watson


HealthNewsDigest.com
BioCryst rallies on gout study; indices diverge
MarketWatch
The NYSE Arca Pharmaceutical Index (INDEX:DRG) was down marginally at 293.68 while the NYSE Arca Biotechnology Index (INDEX:BTK) rose 0.6% to 1178.34.
BioCryst Reports Positive Results from Part One of Its Phase 2a Study of ...MarketWatch (press release)
BioCryst says gout drug shows positive resultsReuters

all 40 news articles »

To Read More: BioCryst rallies on gout study; indices diverge – MarketWatch
categoriaUncategorized commentoComments Off on BioCryst rallies on gout study; indices diverge – MarketWatch | dataApril 29th, 2010
Read All

Biotech Firms Seek Speedier Reviews of Seeds – Truth about Trade & Technology

By Dr. Matthew Watson


France24
Biotech Firms Seek Speedier Reviews of Seeds
Truth about Trade & Technology
The crop-biotechnology industry, growing frustrated as it watches the approval time for new seeds almost double under the Obama ...
Hear Ye, Hear Ye. Judging BiotechnologyCattleNetwork.com
Both Sides Optimistic After US Supreme Court HearingMichigan Farmer
Supreme Court Hears Case on GM Alfalfa BanThe Epoch Times
Iowa Independent -PR Newswire (press release)
all 238 news articles »

To Read More: Biotech Firms Seek Speedier Reviews of Seeds – Truth about Trade & Technology
categoriaUncategorized commentoComments Off on Biotech Firms Seek Speedier Reviews of Seeds – Truth about Trade & Technology | dataApril 29th, 2010
Read All

Charles River Buys Chinese Drug Research Firm – New York Times

By Dr. Matthew Watson


Boston Globe
Charles River Buys Chinese Drug Research Firm
New York Times
The merger reflects the shifting dynamics of the global pharmaceutical and biotechnology industries. Because a major new drug now takes 10 to 15 years and ...
Charles River to buy WuXi for $1.6bBoston Globe
Merger: American firm buys Chinese pharma companyBusiness Review USA
Charles River buys WuXi PharmaTech in $1.6 billion dealFinanceAsia
theasset.com -Mass High Tech -MarketWatch (press release)
all 352 news articles »

To Read More: Charles River Buys Chinese Drug Research Firm – New York Times
categoriaUncategorized commentoComments Off on Charles River Buys Chinese Drug Research Firm – New York Times | dataApril 28th, 2010
Read All

Stem cells for a Webby!

By Dr. Matthew Watson

I know I haven't been a very good blogger for quite some time but I wanted to pass on a letter I just received from my friend James Price as a Charter member of the Canadian Stem Cell Foundation. They're going for a Webby award. You don't have to be Canadian to support their cause - you just have to:

  • believe in the power of interactive, online network-based activism,
  • support the potential of stem cells to change people's lives, and
  • wanna have a little fun raising awareness for our otherwise-sometimes-stodgy-science!

Go vote - it's good for you and the world! (WARNING: you might find out some things about some pretty cool stuff nominated in the other categories while you're there).

CSCFHeader

Dear Lee,

I'd like to thank everyone who has voted and helped spread the word about the Webby Awards nomination. We think a big part of the Foundation's success, and especially this nomination, is due to your enthusiasm, creativity and support.

That support has taken us a long way. Right now, we're in the lead for Best Activism Website. But our lead is narrow, only 3%, so we need you to pull out all the stops. There are only two days left to vote, so let's make sure it's a win for stem cells!

Why Activism?

A large part of what makes our website and social media pages work is the Charter community. All the material we create - the Stem Cell Charter, "Rock Star Scientists" video and all the posts on our social media pages - are designed to give the stem cell movement a voice - your voice. You are the most important part of getting the word out about stem cell science and helping people see the amazing potential of the field.

Voting and encouraging others to vote is a perfect way to do this. Tweet, post, blog, email and shout your support from the rooftops. Let's show the world how important we think stem cell science is.

How to vote

Step 1: Click HERE and fill in your email address and a password.

Step 2: You will receive an email from the Webby Awards - click the link to activate your account.

Step 3: Go HERE TO VOTE and choose RENEW THE WORLD.

Voting closes at midnight on April 29th. We have two days left!

webby banner

Thanks for your support,


James Price
President & CEO



To Read More: Stem cells for a Webby!
categoriaRegenerative Medicine commentoComments Off on Stem cells for a Webby! | dataApril 28th, 2010
Read All

Court hears arguments today on genetic engineering of crops – Trading Markets (press release)

By Dr. Matthew Watson


AFP
Court hears arguments today on genetic engineering of crops
Trading Markets (press release)
Monsanto Co. argued in front of the US Supreme Court this morning that a lower court erred by imposing an injunction that prevents the planting of ...
Court hears arguments today on genetic engineering of cropsSuburbanJournals
Supreme Court hearing on GMO AlfalfaBiofortified (blog)

all 197 news articles »

To Read More: Court hears arguments today on genetic engineering of crops – Trading Markets (press release)
categoriaUncategorized commentoComments Off on Court hears arguments today on genetic engineering of crops – Trading Markets (press release) | dataApril 28th, 2010
Read All

Beetroot Juice May Boost Stamina

By Dr. Matthew Watson

(HealthDay News) -- Beetroot juice can boost physical stamina and increase exercise endurance by up to 16 percent, a new British study shows.

The researchers found that nitrate in beetroot juice reduces oxygen uptake to a degree that can't be achieved by any other means. The findings could benefit endurance athletes, elderly people and those with cardiovascular, respiratory or metabolic diseases, the study authors suggest.

The study included eight men, aged 19 to 38, who drank 500 milliliters a day of organic beetroot juice for six consecutive days. They then completed a series of tests on an exercise bike. The same tests were repeated after the men drank the same amount of a placebo (blackcurrant cordial) for six days.

After drinking the beetroot juice, the men were able to cycle for an average of 11.25 minutes -- 92 seconds longer than after consuming the placebo drink. The men also had a lower resting blood pressure after they drank the beetroot juice, the researchers found.

The study was published Aug. 6 in the Journal of Applied Physiology. Read more...



Joint Mender for Joint Care

To Read More: Beetroot Juice May Boost Stamina
categoriaIntegrative Medicine commentoComments Off on Beetroot Juice May Boost Stamina | dataApril 27th, 2010
Read All

Biomarker Studies Could Realize Goal of More Effective and Personalized Cancer Medicine

By Dr. Matthew Watson

When President Richard Nixon launched the war on cancer in his January 1971 State of the Union, he called for "the same kind of concentrated effort that split the atom and took man to the moon." Yet nearly 40 years and $100 billion in federally funded cancer research later, it seems the lunar landing was a much less daunting task.

[More]

Add to digg
Add to StumbleUpon
Add to Reddit
Add to Facebook
Add to del.icio.us
Email this Article


To Read More: Biomarker Studies Could Realize Goal of More Effective and Personalized Cancer Medicine
categoriaUncategorized commentoComments Off on Biomarker Studies Could Realize Goal of More Effective and Personalized Cancer Medicine | dataApril 27th, 2010
Read All

Sessions on CSC Therapeutics at AACR10

By Dr. Matthew Watson

There were two poster sessions on Cancer Stem Cell Therapeutics at the 101st Annual Meeting of the American Association for Cancer Research (AACR). The sessions, Cancer Stem Cell Therapeutics 1 and Cancer Stem Cell Therapeutics 2, took place on the morning and afternoon of April 20, 2010 [FriendFeed entry].

Two posters presented in the 2nd session have been highlighted in a news release. See: Alchemia’s HyACT Technology Enhances the Killing of Cancer Stem Cell Populations in Breast and Colorectal Cancer, Business Wire, April 20, 2010 [FriendFeed entry]. One of these is Poster #4293: Evaluation of activated CD44 as a biological target in the eradication of breast cancer stem cells, by Vera J Evtimov and Tracey J Brown [Presentation Abstract]. The other is Poster #4278: HA-Irinotecan targeting of activated CD44 is an effective therapy for the eradication of putative colon cancer stem cells [Presentation Abstract].

To Read More: Sessions on CSC Therapeutics at AACR10
categoriaStem Cell Therapy commentoComments Off on Sessions on CSC Therapeutics at AACR10 | dataApril 27th, 2010
Read All

Charles River to buy WuXi for $1.6b – Boston Globe

By Dr. Matthew Watson


Boston Globe
Charles River to buy WuXi for $1.6b
Boston Globe
The alliance is a good fit because the two companies serve a similar client base of leading pharmaceutical and biotechnology companies in the United States ...
Charles River Buys Chinese Drug Research FirmNew York Times (blog)
Merger: American firm buys Chinese pharma companyBusiness Review USA
Charles River buys WuXi PharmaTech in $1.6 billion dealFinanceAsia
theasset.com -Mass High Tech -Daily Metro News
all 301 news articles »

To Read More: Charles River to buy WuXi for $1.6b – Boston Globe
categoriaUncategorized commentoComments Off on Charles River to buy WuXi for $1.6b – Boston Globe | dataApril 27th, 2010
Read All

BOND, STATE AND LOCAL LEADERS BREAK GROUND FOR MISSOURI PLANT SCIENCE CENTER … – BigNews.biz (press release)

By Dr. Matthew Watson


KOMU-TV
BOND, STATE AND LOCAL LEADERS BREAK GROUND FOR MISSOURI PLANT SCIENCE CENTER ...
BigNews.biz (press release)
In addition to the economic impact, Bond stressed the important role biotechnology is playing in revolutionizing human health, the environment and ...
Missouri Plant Science Center Breaks GroundKOMU-TV

all 5 news articles »

To Read More: BOND, STATE AND LOCAL LEADERS BREAK GROUND FOR MISSOURI PLANT SCIENCE CENTER … – BigNews.biz (press release)
categoriaUncategorized commentoComments Off on BOND, STATE AND LOCAL LEADERS BREAK GROUND FOR MISSOURI PLANT SCIENCE CENTER … – BigNews.biz (press release) | dataApril 27th, 2010
Read All

PPD Opens Vaccine Clinical Research Center in Taizhou, China – MarketWatch (press release)

By Dr. Matthew Watson


RTT News
PPD Opens Vaccine Clinical Research Center in Taizhou, China
MarketWatch (press release)
The China Medical City has become a national hub for international and domestic pharmaceutical, biomedical and biotechnology companies and is part of a ...
Pharmaceutical Product 1Q Profit Down 61% On Lower SalesWall Street Journal

all 57 news articles »

To Read More: PPD Opens Vaccine Clinical Research Center in Taizhou, China – MarketWatch (press release)
categoriaUncategorized commentoComments Off on PPD Opens Vaccine Clinical Research Center in Taizhou, China – MarketWatch (press release) | dataApril 26th, 2010
Read All

Lethal fungus strain moving from Canada to US: study – AFP

By Dr. Matthew Watson


MedIndia (press release)
Lethal fungus strain moving from Canada to US: study
AFP
... healthy people," said study co-author Edmond Byrnes, a graduate student at the Duke University Department of Molecular Genetics and Microbiology. ...
New strain of virulent airborne fungi, unique to Oregon, is set to spreadPhysOrg.com
Fungal Disease Spreads Through Pacific NorthwestNPR
Potentially Lethal Airborne Fungus Spreading In USMedical News Today
BusinessWeek -TIME -Tech Jackal
all 188 news articles »

To Read More: Lethal fungus strain moving from Canada to US: study – AFP
categoriaUncategorized commentoComments Off on Lethal fungus strain moving from Canada to US: study – AFP | dataApril 23rd, 2010
Read All

New strain of virulent airborne fungi, unique to Oregon, is set to spread – PhysOrg.com

By Dr. Matthew Watson


ABC News
New strain of virulent airborne fungi, unique to Oregon, is set to spread
PhysOrg.com
Byrnes and other Duke co-authors work in the laboratory of senior author Joseph Heitman, MD, Ph.D., and chair of the Department of Molecular Genetics and ...
Potentially Lethal Airborne Fungus May Spread to CaliforniaU.S. News & World Report
Killer fungus seen in Pacific NorthwestCNN
'Highly Virulent' Strain of Killer Fungus Found in Ore.AOL News
LiveScience.com
all 66 news articles »

To Read More: New strain of virulent airborne fungi, unique to Oregon, is set to spread – PhysOrg.com
categoriaUncategorized commentoComments Off on New strain of virulent airborne fungi, unique to Oregon, is set to spread – PhysOrg.com | dataApril 22nd, 2010
Read All

High Red Meat Consumption Linked to Colon Cancer

By Dr. Matthew Watson

NEW YORK (Reuters Health) - Long-term high consumption of red and processed meat may increase the risk of cancer in the colon and rectum, a new study shows.

Dr. Michael J. Thun, with the American Cancer Society in Atlanta, and colleagues followed 148,610 adults, average age 63 years, who completed questionnaires in 1982 and again between 1992 and 1993 regarding their diet, exercise, medical history and other lifestyle habits.

By 2001, there were 1667 new cases of colorectal cancer, according to a report in Wednesday's Journal of the American Medical Association.

The participants who consistently ate the most red meat and processed meats had a 50 percent higher rate colorectal cancer than those who ate the least red or processed meat.

Prolonged high consumption of poultry and fish was marginally associated with about a 25 percent lower risk of colon cancer, but not rectal cancer. Read more...

Ayurtox for Body Detoxification

To Read More: High Red Meat Consumption Linked to Colon Cancer
categoriaIntegrative Medicine commentoComments Off on High Red Meat Consumption Linked to Colon Cancer | dataApril 21st, 2010
Read All

Rare flowers and common herbal supplements get unmasked with plant DNA barcoding

By Dr. Matthew Watson

NEW YORK--Will exotic orchids soon be subjected to the same genetic scrutiny as some luxury caviars? That is just one of the coding conundrums that scientists convened at the New York Botanical Garden in the Bronx to discuss on a cloudy mid-April afternoon. [More]

Add to digg
Add to StumbleUpon
Add to Reddit
Add to Facebook
Add to del.icio.us
Email this Article


To Read More: Rare flowers and common herbal supplements get unmasked with plant DNA barcoding
categoriaUncategorized commentoComments Off on Rare flowers and common herbal supplements get unmasked with plant DNA barcoding | dataApril 20th, 2010
Read All

Page 611«..1020..610611612613